<DOC>
	<DOCNO>NCT01601353</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy adipose derive cell treatment erectile dysfunction symptom .</brief_summary>
	<brief_title>Evaluate Use Liposuction Cell Separation Devices Autologous Fat ( Adipose ) Derived Cells Treat Symptoms Erectile Dysfunction</brief_title>
	<detailed_description>This trial conduct determine safety efficacy inject autologous adipose derived cell penis men erectile dysfunction . Subjects randomized treatment control arm .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>1 . Men age 40 70 2 . Willing able provide write informed consent 3 . Chronic , organic erectile dysfunction ( ED ) , duration least 0.5 year , baseline International Index Erectile Function Erectile Function ( IIEFEF ) score &lt; 26 4 . Willing complete questionnaire 5 . Involved monogamous , heterosexual relationship least 3 month partner motivate attempt sexual intercourse least 4 time per month begin two week study treatment ( subject report ) 6 . Not interested able use oral PDE5 inhibitor ( PDE5i ) drug therapy , willing forgo treatment first 6month period follow study treatment ( addition may include minimum 4week washout since last PDE5i use prior completion baseline erectile function assessment study treatment ) 7 . Willing limit alcohol intake eliminate use recreational drug sexual encounter 8 . Willing undergo minor surgical procedure injection 9 . Abdominal area amenable liposuction least 60120 cc adipose tissue base Investigator examination 10 . Mentally competent able understand study requirement ( base investigator assessment ) 11 . Willing available baseline , treatment followup examination require protocol 12 . Willing forego participation study throughout duration study unless receive prior approval Sponsor . 1 . Evidence prostate cancer require additional radiotherapy adjuvant therapy 2 . Previous pelvic abdominal radiation therapy 3 . Previous , concomitant schedule use antiandrogen therapy 4 . Untreated hypogonadism low serum total testosterone ( &lt; 200 ng/dL ) 5 . Clinically evident penile anatomical deformity ( e.g. , Peyronie 's disease ) history priapism 6 . Skin irritation , infection , wound , sore disruption immediate area skin entry abdominal liposuction penile injection ( include abdominal trauma abdominal skin cancer ( basal cell carcinoma , squamous cell carcinoma , melanoma ) ) 7 . Use nonstudy treatment erectile dysfunction within 4 week study treatment lack willingness continue 6 month study treatment 8 . Any previous penile implant penile vascular surgery 9 . Current previous malignancy localize prostate cancer nonabdominal , nonmelanoma skin cancer ( successfully treat treatable curative excision local curative therapy abdominal skin cancer exclusionary indicate criterion 6 ) 10 . Uncontrolled hypertension hypotension ( systolic blood pressure &gt; 170 &lt; 90 mm Hg , diastolic blood pressure &gt; 100 &lt; 50 mm Hg ) 11 . Reported unstable cardiovascular disease ( e.g. , unstable angina , myocardial infarction within past 6 month , cardiac failure lifethreatening arrhythmia , congestive heart failure ) symptomatic postural hypotension within 6 month screen 12 . Hemoglobin A1c &gt; 8 % within 8 week prior study treatment 13 . Current urinary tract bladder infection 14 . Drug , alcohol , substance abuse report within last three year ( subject report ) 15 . Subject 's sexual partner &lt; 18 year age , nursing , know pregnant screening , wish become pregnant study period , gynecologic problem , major medical condition , factor would limit participation sexual intercourse le 4 time per month ( subject report ) 16 . Weight le 154 lbs/ 70 kg , BMI â‰¥ 30 17 . Unable limit avoid nonsteroidal antiinflammatory drug ( NSAIDs ) 15 day prior treatment ( subject report ) 18 . Bleeding clot disorder , use anticoagulant therapy , history easy excessive bruising 19 . Lab value Complete Blood Count ( CBC ) , Prothrombin Time ( PT ) /Partial Thromboplastin Time ( PTT ) /International Normalized Ration ( INR ) , liver function creatinine fall outside normal lab value ( see section 5.3 detail ) 20 . Systemic autoimmune disorder 21 . Significant active systemic localize infection 22 . Receiving immunosuppressant medication</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Erectile Dysfunction</keyword>
</DOC>